Health and Fitness Health and Fitness
Thu, September 6, 2012
Wed, September 5, 2012
Tue, September 4, 2012
Mon, September 3, 2012
Sun, September 2, 2012
Sat, September 1, 2012
Fri, August 31, 2012
Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012
Mon, August 27, 2012
Sun, August 26, 2012
Sat, August 25, 2012
Fri, August 24, 2012
Thu, August 23, 2012

ArQule, Inc. to Present at Upcoming Investment Conferences


//health-fitness.news-articles.net/content/2012/ .. -present-at-upcoming-investment-conferences.html
Published in Health and Fitness on Thursday, August 30th 2012 at 5:48 GMT by Market Wire   Print publication without navigation


WOBURN, Mass.--([ ])--ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the following upcoming conferences.

  • Stifel Nicolaus 2012 Healthcare Conference, Thursday, September 6, 2012, 10:55 a.m.
  • Newsmakers in the Biotech Industry Conference, Friday, September 7, 2012, 2:30 p.m.
  • Morgan Stanley Global Healthcare Conference, Monday, September 10, 2012, 2:25 p.m.

The presentations will be web cast and may be accessed through the investor relations section of the Companyas website, [ http://www.arqule.com ].

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Companyas targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQuleas lead product candidate, in Phase 2 and Phase 3 clinical development together with development and commercialization partner, Daiichi Sankyo, Co. Ltd., is tivantinib, an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Companyas pipeline consists of ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and ARQ 736, designed to inhibit the RAF kinases. ArQuleas current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIPa"), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.


Publication Contributing Sources